The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Parathyroid Hormone Global Market Report 2024, the parathyroid hormone market is expected to show promising growth in the forecast period.

Introduction: A Steady Rise in Market Size

The parathyroid hormone market has experienced steady growth in recent years, with its size projected to increase from $2.35 billion in 2023 to $2.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 3.5%. This growth is attributed to various factors driving demand and innovation in parathyroid hormone-related treatments.

Elevated Prevalence Of Osteoporosis Sparks Growth In The Parathyroid Hormone Market

• Osteoporosis prevalence rises, fueling demand for parathyroid hormone-based treatments.
• Parathyroid hormone helps reduce fracture risk in osteoporosis patients.
• Major companies in the market include Pfizer Inc., Eli Lilly and Company, and Novartis AG.

Biosimilar Development In The Parathyroid Hormone Market Enhances Affordability And Treatment Standards

• Companies focus on developing biosimilars of parathyroid-based drugs to enhance affordability.
• Biosimilars offer reduced healthcare costs without compromising treatment standards.
• Theramex launched Livogiva, a novel form of teriparatide, for osteoporosis treatment.

View More On The Parathyroid Hormone Market Report 2024 – https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Takeda’s Strategic Acquisition Of Shire PLC Fuels Global Expansion

• Takeda Pharmaceutical Company Limited acquires Shire Plc for $46 billion.
• The acquisition expands Takeda’s scale and geographical footprint.
• Shire Plc specializes in innovative and rare disease drugs, including natpara, a parathyroid hormone product.

Segmentation Insights and Regional Trends

1. Disease Type:
   • Hypocalcemia
   • Hypoparathyroidism
2. Product Type:
   • Recombinant Parathyroid Hormone
   • Parathyroid Hormone Analogues
3. End-User:
   • Hospitals
   • Clinics
   • Other End-Users

Regional Dynamics: Insights into Market Share

• North America dominated the parathyroid hormone market in 2023.
• The Middle East is poised to exhibit the fastest-growing region in the global market share during the forecast period.

Future Outlook: Embracing Transformative Trends

• The forecast period anticipates advances in parathyroid hormone testing and drug delivery.
• Combination therapies and digital health integration are expected to shape future treatment landscapes.
• Sustainability and green initiatives are likely to influence product development and manufacturing processes.

Conclusion: Navigating Towards Growth and Innovation

The parathyroid hormone market presents promising opportunities for growth and innovation. With the rising prevalence of osteoporosis and increasing investments in biosimilar development, the market is poised for expansion. Strategic acquisitions and partnerships, such as Takeda’s acquisition of Shire PLC, underscore the industry’s commitment to global expansion and enhanced treatment access. As the market evolves, embracing segmentation insights and regional trends will be essential for stakeholders to navigate towards a future marked by sustained growth and improved patient outcomes.

Request A Sample Of The Global Parathyroid Hormone Market Report 2024:

https://www.thebusinessresearchcompany.com/sample_request?id=3427&type=smp